| Previous Close | 81.52 |
| Open | 81.59 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 81.25 - 82.56 |
| 52 Week Range | 24.55 - 92.97 |
| Volume | 1,692,648 |
| Avg. Volume | 1,903,558 |
| Market Cap | 100.14B |
| Beta | 0.73 |
| PE Ratio (TTM) | 11.47 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.40%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Market Realist•yesterday
Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.
- Market Realist•4 days ago
Label Expansion in Asthma Indication May Boost Dupixent’s Sales
Dupixent combined with standard of care also showed 12%–15% improvement in FEV1 from baseline in asthma patients after 12 weeks of treatment compared to those treated with standard of care alone.
- Market Realist•4 days ago
Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis
As a treatment option for adult AD patients eligible for systemic therapy, Dupixent is expected to be approved in the European Union in 3Q17.
